Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1418810 | 0.86 | ALDH1A1 (0.57) | MAPTRAB9AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL1418819 | 0.84 | SCN1A (0.40) | GAAMAPTRAB9APOLBNR4A1 | |
| SCHEMBL7320242 | 0.83 | ALDH1A1 (0.52) | RAB9APOLBALDH1A1KMT2AMEN1 | |
| SCHEMBL5263982 | 0.82 | KMT2A (0.58) | RAB9APOLBALDH1A1KMT2AMEN1 | |
| SCHEMBL7469487 | 0.82 | LMNA (0.56) | GAARAB9APOLBKMT2AMEN1 | |
| SCHEMBL25438215 | 0.82 | HDAC3 (0.42) | GAAMAPTKMT2AMEN1L3MBTL1 | |
| SCHEMBL2031182 | 0.82 | ALDH1A1 (0.50) | MAPTRAB9APOLBALDH1A1KMT2A | |
| SCHEMBL6973545 | 0.82 | MEN1 (0.49) | MAPTPOLBKMT2AMEN1L3MBTL1 | |
| SCHEMBL3111441 | 0.82 | CA1 (0.51) | MAPTL3MBTL1CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL1418852 | 0.81 | MAPT (0.48) | MAPTALDH1A1KMT2AMEN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201178-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2023-06-29 | — | — | US | claimed |
| US-20210137901-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2021-05-13 | — | — | US | claimed |
| US-10729681-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS, INC. (US) | 2020-08-04 | — | — | US | claimed |
| US-20190192494-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2019-06-27 | — | — | US | claimed |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2016-09-15 | — | — | US | claimed |
| EP-2456435-B1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | UNIV LELAND STANFORD JUNIOR (US) | 2015-06-24 | — | — | EP | claimed |
| EP-2430013-B1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC (US) | 2014-10-15 | — | — | EP | claimed |
| US-20130184222-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2013-07-18 | — | — | US | claimed |
| EP-2593425-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | Agios Pharmaceuticals, Inc. (US) | 2013-05-22 | — | — | EP | claimed |
| CN-103097340-A | Therapeutically active compositions and methods of use thereof | AGIOS PHARMACEUTICALS INC | 2013-05-08 | — | — | CN | claimed |
| WO-2011011514-A1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2011-01-27 | — | — | WO | claimed |
| WO-2010132598-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC. (US) | 2010-11-18 | — | — | WO | claimed |
| US-20090044863-A1 | CORONENE CHARGE-TRANSPORT MATERIALS, METHODS OF FABRICATION THEREOF, AND METHODS OF USE THEREOF | NATIONAL SCIENCE FOUNDATION | 2009-02-19 | — | — | US | claimed |
| US-20080223444-A1 | Perylene Charge-Transport Materials, Methods of Fabrication Thereof, and Methods of Use Thereof | GEORGIA TECH RESEARCH CORPORATION | 2008-09-18 | — | — | US | claimed |
| WO-2006093965-A2 | CORONENE CHARGE-TRANSPORT MATERIALS, METHODS OF FABRICATION THEREOF, AND METHODS OF USE THEREOF | GEORGIA TECH RESEARCH CORPORATION (US) | 2006-09-08 | — | — | WO | claimed |
| CN-1829721-A | Spiro '1-azabicyclo' 2.2.2! octan-3,5'-oxazolidin - 2'-one! derivatives with affinity to the alpha7 nicotinic acetylcholine receptor | ASTRAZENECA AB (SE) | 2006-09-06 | — | — | CN | claimed |
| US-20060025345-A1 | Substituted ethane-1,2-diamines for the treatment of Alzheimer's disease | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-02 | — | — | US | claimed |
| WO-2005124453-A2 | PERYLENE CHARGE-TRANSPORT MATERIALS, METHODS OF FABRICATION THEREOF, AND METHODS OF USE THEREOF | GEORGIA TECH RESEARCH CORPORATION (US) | 2005-12-29 | — | — | WO | claimed |
| WO-2005113582-A1 | SUBSTITUTED ETHANE-1,2-DIAMINES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-01 | — | — | WO | claimed |
| US-4032652-A | SUBSTITUTED 2H-PYRAN-2,6(3H)-DIONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH DERIVATIVES AND METHODS OF INHIBITING THE ANTIGEN-ANTIBODY REACTION | SMITHKLINE CORPORATION (US) | 1977-06-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025345-A1 | Substituted ethane-1,2-diamines for the treatment of Alzheimer's disease | PSEN1, PSEN2, APP | GAA 1640/4885MAPT 47/4885RAB9A 373/4885 |
| US-20190192494-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | GAA 139/4885MAPT 4669/4885RAB9A 4097/4885 |
| US-20210137901-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | GAA 139/4885MAPT 4669/4885RAB9A 4097/4885 |
| US-20230201178-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | GAA 139/4885MAPT 4669/4885RAB9A 4097/4885 |
| US-20130184222-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | GAA 102/4885MAPT 2881/4885RAB9A 1278/4885 |
| US-20080223444-A1 | Perylene Charge-Transport Materials, Methods of Fabrication Thereof, and Methods of Use Thereof | SLC43A1, SLC3A2, SLC16A3 | GAA 2697/4885MAPT 1950/4885RAB9A 762/4885 |
| US-10729681-B2 | Prolyl hydroxylase inhibitors and methods of use | HIF1AN, EGLN3, HIF1A | GAA 139/4885MAPT 4669/4885RAB9A 4097/4885 |
| US-20090044863-A1 | CORONENE CHARGE-TRANSPORT MATERIALS, METHODS OF FABRICATION THEREOF, AND METHODS OF USE THEREOF | SLC18A3, CORO1C, SLC18A1 | GAA 2175/4885MAPT 2534/4885RAB9A 1186/4885 |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | GAA 102/4885MAPT 2881/4885RAB9A 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.